Avastin is FDA approved to treat Cervical Cancer - Genentech/Roche
Genentech/Roche has announced that the FDA approved Avastin (bevacizumab) in combination with paclitaxel and cisplatin or paclitaxel and topotecan for the treatment of women with persistent, recurrent or metastatic Carcinoma of the Cervix. With this approval in advanced Cervical Cancer, Avastin is approved in the United States to treat five distinct tumor types. The approval in advanced Cervical Cancer was based on the GOG-0240 study. Avastin is the first drug approved for patients with late-stage Cervical Cancer since the 2006 approval of topotecan with cisplatin.
150 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.